Current treatment status-Undergoing active treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment Posts on Medivizor

EndoPredict – can this prognostic test predict treatment success in breast cancer?

Posted by on May 30, 2019 in Breast cancer | 0 comments

In a nutshell This study investigated if a prognostic tool called EndoPredict can predict the success of treatment in hormone receptor-positive breast cancer (BC). They found that high scores using EndoPredict predicted treatment benefit in patients with BC.  Some background Breast cancer (BC) is one of the most common cancers. BC treatment...

Read More

Evaluating isatuximab plus pomalidomide and dexamethasone for non-responsive multiple myeloma

Posted by on May 11, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated  isatuximab, pomalidomide (Imnovid) and dexamethasone (Decadron) for recurrent or non-responsive multiple myeloma (MM). This study concluded that this treatment combination was safe and effective for these patients. Some background There are several treatment options for patients with MM. Most initial...

Read More

Evaluating scoring systems used to predict outcomes for patients with advanced HL

Posted by on Apr 24, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the effectiveness of the International Prognostic Scoring System (IPSS) measuring 7 factors (IPSS7) versus the IPSS measuring 3 factors (IPSS3) in predicting outcomes for patients with Hodgkin's lymphoma (HL). This study concluded that there was no significant difference between these scoring systems. Some...

Read More

Can molecular monitoring help treatment and outcomes in patients with chronic myeloid leukemia?

Posted by on Jan 12, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the use of molecular monitoring to assess outcomes in patients with chronic myeloid leukemia. Researchers found that molecular monitoring at 3 and 12 months is beneficial to these patients. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This leads to an abnormal immune system and...

Read More

Risk of hepatitis B reactivation in patients with lymphomas receiving obinutuzumab or rituximab

Posted by on Jan 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the risk of reactivating hepatitis B (HBV) infection in patients with lymphoma treated with obinutuzumab (Gazyva) or rituximab (Rituxan). Researchers found that HBV infection was reactivated in some of these patients but treatment options are available. Some background Lymphoma is a cancer of the immune system....

Read More

Evaluating the impact of early PET/CT scanning on survival in patients with lymphoma after stem cell transplant

Posted by on Dec 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...

Read More

Evaluating the impact of early PET/CT scanning on survival in patients with lymphoma after stem cell transplant

Posted by on Dec 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...

Read More

Evaluating the impact of early PET/CT scanning on survival in patients with lymphoma after stem cell transplant

Posted by on Dec 27, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...

Read More

Re-treatment with cetuximab improves cancer outcomes in patients with inoperable colorectal cancer

Posted by on Dec 23, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effect of cetuximab (Erbitux) in patients with metastatic (spread to other parts of the body) colorectal cancer who did not respond to initial cetuximab treatment. Researchers suggested that this treatment may be beneficial in longer treatment durations. Some background The standard treatment for patients...

Read More

Long term results discussing radiotherapy and hormone therapy treatments for patients with prostate cancer

Posted by on Dec 16, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate whole pelvic radiotherapy (WPRT) compared to prostate only radiotherapy (PORT) with hormonal therapy (HT) before or after radiation for patients with intermediate- or high-risk prostate cancer. This study found that HT before radiotherapy and WPRT had superior long-term survival without cancer growing or...

Read More